[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR112017008106A2 - polipeptídeo de ligação a fc, multímero, ácido nucleico ou vetor, sistema de expressão, matriz de separação, e, método para isolar uma imunoglobina. - Google Patents

polipeptídeo de ligação a fc, multímero, ácido nucleico ou vetor, sistema de expressão, matriz de separação, e, método para isolar uma imunoglobina.

Info

Publication number
BR112017008106A2
BR112017008106A2 BR112017008106-7A BR112017008106A BR112017008106A2 BR 112017008106 A2 BR112017008106 A2 BR 112017008106A2 BR 112017008106 A BR112017008106 A BR 112017008106A BR 112017008106 A2 BR112017008106 A2 BR 112017008106A2
Authority
BR
Brazil
Prior art keywords
seq
binding polypeptide
immunoglobin
multimer
isolating
Prior art date
Application number
BR112017008106-7A
Other languages
English (en)
Inventor
Rodrigo Gustav
BJORKMAN Tomas
ANDER Mats
Original Assignee
Ge Healthcare Bioprocess R&D Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1510263.5A external-priority patent/GB201510263D0/en
Priority claimed from GBGB1510261.9A external-priority patent/GB201510261D0/en
Application filed by Ge Healthcare Bioprocess R&D Ab filed Critical Ge Healthcare Bioprocess R&D Ab
Publication of BR112017008106A2 publication Critical patent/BR112017008106A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G, L chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804—Affinity chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/281—Sorbents specially adapted for preparative, analytical or investigative chromatography
    • B01J20/286—Phases chemically bonded to a substrate, e.g. to silica or to polymers
    • B01J20/289—Phases chemically bonded to a substrate, e.g. to silica or to polymers bonded via a spacer
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/30—Processes for preparing, regenerating, or reactivating
    • B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
    • B01J20/3214—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the method for obtaining this coating or impregnating
    • B01J20/3217—Resulting in a chemical bond between the coating or impregnating layer and the carrier, support or substrate, e.g. a covalent bond
    • B01J20/3219—Resulting in a chemical bond between the coating or impregnating layer and the carrier, support or substrate, e.g. a covalent bond involving a particular spacer or linking group, e.g. for attaching an active group
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/30—Processes for preparing, regenerating, or reactivating
    • B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
    • B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
    • B01J20/3242—Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
    • B01J20/3268—Macromolecular compounds
    • B01J20/3272—Polymers obtained by reactions otherwise than involving only carbon to carbon unsaturated bonds
    • B01J20/3274—Proteins, nucleic acids, polysaccharides, antibodies or antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)

Abstract

um polipeptídeo de ligação a fc de estabilidade alcalina melhorada, compreendendo um mutante de um domínio de ligação a fc de proteína a de staphylococcus (spa), como definido pela seq id no: 1, seq id no: 2, seq id no:3, seq id no: 4, seq id no: 5, seq id no:6, seq id no:7, seq id no:22, seq id no 51 ou seq id no 52, em que pelo menos o resíduo de asparagina ou serina na posição correspondente à posição 11 na seq id no:4-7 foi mutado para um aminoácido selecionado do grupo que consiste em ácido glutâmico, lisina, tirosina, treonina, fenilalanina, leucina, isoleucina, triptofano, metionina, valina, alanina, histidina e arginina.
BR112017008106-7A 2014-11-17 2015-11-16 polipeptídeo de ligação a fc, multímero, ácido nucleico ou vetor, sistema de expressão, matriz de separação, e, método para isolar uma imunoglobina. BR112017008106A2 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
SE1451376-6 2014-11-17
SE1451376 2014-11-17
GB1510263.5 2015-06-12
GB1510261.9 2015-06-12
GBGB1510263.5A GB201510263D0 (en) 2015-06-12 2015-06-12 Mutated immunoglobulin-binding polypeptides
GBGB1510261.9A GB201510261D0 (en) 2015-06-12 2015-06-12 Mutated immunoglobulin-binding polypeptides
PCT/EP2015/076639 WO2016079033A1 (en) 2014-11-17 2015-11-16 Mutated immunoglobulin-binding polypeptides

Publications (1)

Publication Number Publication Date
BR112017008106A2 true BR112017008106A2 (pt) 2018-03-06

Family

ID=54695687

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017008106-7A BR112017008106A2 (pt) 2014-11-17 2015-11-16 polipeptídeo de ligação a fc, multímero, ácido nucleico ou vetor, sistema de expressão, matriz de separação, e, método para isolar uma imunoglobina.

Country Status (14)

Country Link
US (5) US11566082B2 (pt)
EP (4) EP3757124A1 (pt)
JP (5) JP6724000B2 (pt)
KR (2) KR102552335B1 (pt)
CN (3) CN118546242A (pt)
AU (2) AU2015348641B2 (pt)
BR (1) BR112017008106A2 (pt)
DE (1) DE112015005181T5 (pt)
DK (2) DK3221347T3 (pt)
ES (1) ES2817900T3 (pt)
RU (2) RU2701695C2 (pt)
SG (2) SG11201703053PA (pt)
SI (1) SI3221347T1 (pt)
WO (2) WO2016079034A1 (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0200943D0 (sv) * 2002-03-25 2002-03-25 Amersham Biosciences Ab Mutant protein
US11566082B2 (en) * 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
JP6843438B2 (ja) 2014-12-17 2021-03-17 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 改変κ軽鎖結合ポリペプチド
JP6891114B2 (ja) * 2015-07-22 2021-06-18 株式会社カネカ 酸性ｐＨ領域での抗体結合能が低下した抗体結合性タンパク質
GB201515339D0 (en) * 2015-08-28 2015-10-14 Ge Healthcare Bio Sciences Ab A seperation matrix and a method of seperating antibodies
CN109310780A (zh) 2016-05-04 2019-02-05 纳维格蛋白质有限公司 包含肽接头的用于化学部分位点-特异性偶联的靶向化合物
ES2909833T3 (es) * 2016-05-11 2022-05-10 Cytiva Bioprocess R & D Ab Método de limpieza y/o desinfección de una matriz de separación
WO2017194596A1 (en) * 2016-05-11 2017-11-16 Ge Healthcare Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
JP7106187B2 (ja) * 2016-05-11 2022-07-26 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックスを保存する方法
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
JP7031934B2 (ja) 2016-05-11 2022-03-08 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックス
WO2017194597A1 (en) 2016-05-11 2017-11-16 Ge Healthcare Bioprocess R&D Ab Separation matrix
CN109219613B (zh) * 2016-05-11 2022-09-23 思拓凡生物工艺研发有限公司 分离方法
EP4324840A3 (en) * 2016-08-11 2024-04-24 Navigo Proteins GmbH Novel alkaline stable immunoglobulin-binding proteins
GB201703116D0 (en) 2017-02-27 2017-04-12 Ge Healthcare Bioprocess R&D Ab A seperation matrix and a method of seperating antibodies
EP3592759A1 (en) * 2017-03-07 2020-01-15 JMVA Biotech AB Modified adsorptive surfaces
GB201708277D0 (en) 2017-05-24 2017-07-05 Ge Healthcare A Recombinant protein
EP3521304B9 (en) * 2018-02-01 2023-10-04 Repligen Corporation Fc binding proteins with cysteine in the c-terminal helical region
WO2019030156A1 (en) * 2017-08-07 2019-02-14 Repligen Corporation FC BINDING PROTEINS WITH CYSTEINE IN THE C-TERMINAL HELICAL REGION
EP3546476A1 (en) * 2018-03-26 2019-10-02 Repligen Corporation Fc binding proteins with cysteine in the c-terminal helical region
US11709156B2 (en) 2017-09-18 2023-07-25 Waters Technologies Corporation Use of vapor deposition coated flow paths for improved analytical analysis
US11709155B2 (en) 2017-09-18 2023-07-25 Waters Technologies Corporation Use of vapor deposition coated flow paths for improved chromatography of metal interacting analytes
WO2019091918A1 (en) 2017-11-07 2019-05-16 Navigo Proteins Gmbh Fusion proteins with specificity for ed-b and long serum half-life for diagnosis or treatment of cancer
US11629168B2 (en) 2017-11-09 2023-04-18 Tosoh Corporation Immunoglobulin-binding protein
GB2569585A (en) 2017-12-20 2019-06-26 Ge Healthcare Bio Sciences Ab A method for preparation of a separation matrix
GB201800448D0 (en) * 2018-01-11 2018-02-28 Puridify Ltd Chromatography media and methods for producing them
EA202092316A1 (ru) 2018-03-28 2021-05-25 Бристол-Маерс Сквибб Компани Слитые белки интерлейкина-2/альфа-рецептора интерлейкина-2 и способы применения
JP7492463B2 (ja) 2018-07-03 2024-05-29 ブリストル－マイヤーズ スクイブ カンパニー Ｆｇｆ－２１製剤
KR20210049802A (ko) * 2018-08-24 2021-05-06 제이에스알 가부시끼가이샤 이뮤노글로불린 결합 단백질 및 그것을 사용한 어피니티 담체
JP7573287B2 (ja) * 2019-02-01 2024-10-25 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツング アフィニティー精製用免疫グロブリン結合タンパク質
GB201904125D0 (en) 2019-03-26 2019-05-08 Ge Healthcare Bio Sciences Ab Method for sanitization of a chromatography column
JP7432813B2 (ja) * 2019-09-10 2024-02-19 東ソー株式会社 免疫グロブリン結合性タンパク質
JP2022551837A (ja) * 2019-10-08 2022-12-14 ノース カロライナ ステート ユニバーシティ 免疫グロブリン精製ペプチド、及びその使用
US11918936B2 (en) 2020-01-17 2024-03-05 Waters Technologies Corporation Performance and dynamic range for oligonucleotide bioanalysis through reduction of non specific binding
WO2022081779A1 (en) 2020-10-13 2022-04-21 Avitide LLC Affinity ligand libraries of three-helix bundle proteins and uses thereof
CN117241866A (zh) 2021-02-19 2023-12-15 艾维泰有限责任公司 Aav2亲和剂
GB202113626D0 (en) 2021-09-24 2021-11-10 Cytiva Bioprocess R & D Ab FC binding polypeptides
GB202203478D0 (en) 2022-03-14 2022-04-27 Cytiva Bioprocess R & D Ab Vh3 binding polypeptides
CN117700501A (zh) * 2022-09-13 2024-03-15 普米斯生物技术(珠海)有限公司 免疫球蛋白结合蛋白及其应用

Family Cites Families (166)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE451946B (sv) 1982-12-10 1987-11-09 Gambro Lundia Ab Anordning for avlegsnande av en eller flera fraktioner ur helblod, plasma eller liknande kroppsvetskor
US4704366A (en) 1984-06-22 1987-11-03 Bio-Rad Laboratories, Inc. Process for binding IgG to protein A
SE8505922D0 (sv) 1985-12-13 1985-12-13 Kabigen Ab Construction of an igg binding protein to facilitate downstream processing using protein engineering
US4801687A (en) 1986-10-27 1989-01-31 Bioprobe International, Inc. Monoclonal antibody purification process using protein A
AU612370B2 (en) 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
US5011686A (en) 1987-09-21 1991-04-30 Creative Biomolecules, Inc. Thrombus specific conjugates
US5084398A (en) 1987-11-20 1992-01-28 Creative Biomolecules Selective removal of immune complexes
US4933435A (en) 1989-04-05 1990-06-12 Bioprobe International Antibody purification process
EP0550771B1 (en) 1991-07-25 1999-09-29 Oriental Yeast Co., Ltd. Immunoglobulin-binding artificial protein
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
SE9503925D0 (sv) 1995-11-07 1995-11-07 Pharmacia Biotech Ab Separationsmedium för IgG
SE9601368D0 (sv) 1996-04-11 1996-04-11 Pharmacia Biotech Ab Process for the production of a porous cross-linked polysaccharide gel
DE69739673D1 (de) 1996-11-27 2009-12-31 Genentech Inc Affinitätsreinigung von Polypeptid-Proteinen auf einer Protein A Matrix
EP1472275B1 (en) 2002-02-05 2008-12-17 Genentech, Inc. Protein purification
SE0200943D0 (sv) * 2002-03-25 2002-03-25 Amersham Biosciences Ab Mutant protein
US7709209B2 (en) 2002-03-25 2010-05-04 Ge Healthcare Bio-Sciences Ab Protein ligands
AU2003272368C1 (en) 2002-09-13 2009-07-23 Biogen Idec Inc. Method of purifying polypeptides by simulated moving bed chromatography
AU2003298787A1 (en) 2002-11-27 2004-06-23 Gtc Biotherapeutics, Inc. Modified antibodies stably produced in milk and methods of producing same
US8084032B2 (en) 2004-01-21 2011-12-27 Ajinomoto Co., Inc. Purification method which prevents denaturation of an antibody
SE0400274D0 (sv) 2004-02-09 2004-02-09 Affibody Ab New polypeptide
SE0402322D0 (sv) 2004-09-22 2004-09-22 Amersham Biosciences Ab Method of preparing a chromatography matrix
JP2006304633A (ja) 2005-04-26 2006-11-09 Apro Life Science Institute Inc イムノグロブリン結合タンパク質
CA2611815A1 (en) 2005-06-17 2006-12-28 Elan Pharma International Limited Methods of purifying anti a beta antibodies
MX2008002101A (es) 2005-08-12 2008-04-19 Schering Corp Fusiones de la proteina-1 quimiotactica de monocito.
AU2007204987B2 (en) 2006-01-06 2011-11-24 Amgen Inc. Methods and systems for isolating target molecules from complex solutions by column-chromatography using eluants containing organic solvents
WO2007084922A2 (en) 2006-01-17 2007-07-26 Biolex Therapeutics, Inc. Compositions and methods for humanization and optimization of n-glycans in plants
US8674073B2 (en) 2006-02-21 2014-03-18 Protenova Co., Ltd. Immunoglobulin affinity ligand
WO2007109163A2 (en) 2006-03-16 2007-09-27 Amgen Inc Wash buffer and method of using
WO2007112005A2 (en) 2006-03-24 2007-10-04 Syntonix Pharmaceuticals, Inc. Pc5 as a factor ix propeptide processing enzyme
US8377448B2 (en) 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
WO2007144476A1 (fr) 2006-06-16 2007-12-21 Groupe Novasep Procede de separation sequence multicolonnes
PT1873166E (pt) 2006-06-30 2010-12-09 Conaris Res Inst Ag Dímeros de sgp130fc melhorados
NZ574623A (en) 2006-08-28 2011-12-22 Ares Trading Sa Process for the purification of fc-fusion proteins
BRPI0716597A2 (pt) 2006-09-08 2013-10-08 Wyeth Corp Método para o isolamento de um produto; produto preparado pelo método; método para o isolamento de um anticorpo; método para reduzir a turvação de um eluído compreendendo em produto; e método para reduzir a turvação e impurezas de um eluído compreendendo um produto
CN106422418B (zh) 2006-09-29 2022-03-01 思拓凡生物工艺研发有限公司 用于抗体分离的包含来自金黄色葡萄球菌a蛋白的结构域c的层析配体
WO2008049106A2 (en) 2006-10-19 2008-04-24 Centocor Ortho Biotech Inc. Process for preparing unaggregated antibody fc domains
EP2099932A4 (en) * 2006-12-06 2009-11-18 Repligen Corp NUCLEIC ACIDS ENCODING THE RECOMBINANT PROTEIN A
WO2008085988A1 (en) 2007-01-05 2008-07-17 Amgen Inc. Methods of purifying proteins
JP5522723B2 (ja) * 2007-05-21 2014-06-18 ノマディックバイオサイエンス株式会社 新規ポリペプチド，アフィニティークロマトグラフィー用材，及びイムノグロブリンの分離及び／又は精製方法
US7901581B2 (en) 2007-06-15 2011-03-08 Ge Healthcare Bio-Sciences Ab Chromatography method
JP2011518790A (ja) 2008-04-23 2011-06-30 シムフォゲン・アクティーゼルスカブ ポリクローナルタンパク質を製造する方法
US8592555B2 (en) * 2008-08-11 2013-11-26 Emd Millipore Corporation Immunoglobulin-binding proteins with improved specificity
SG2013061528A (en) 2008-08-14 2015-03-30 Merck Sharp & Dohme Methods for purifying antibodies using protein a affinity chromatography
JP5229888B2 (ja) 2008-09-30 2013-07-03 独立行政法人産業技術総合研究所 弱酸性域での易解離性を向上したプロテインａ変異型タンパク質及び抗体捕捉剤
US8183207B2 (en) 2008-11-26 2012-05-22 Five Prime Therapeutics, Inc. Treatment of osteolytic disorders and cancer using CSF1R extracellular domain fusion molecules
WO2010062399A2 (en) 2008-11-26 2010-06-03 Five Prime Therapeutics, Inc. Csf1r extracellular domain fusion molecules and treatments using same
SG195555A1 (en) 2008-12-24 2013-12-30 Emd Millipore Corp Caustic stable chromatography ligands
US9403883B2 (en) 2009-03-24 2016-08-02 Kaneka Corporation Protein having affinity for immunoglobulin, and immunoglobulin-binding affinity ligand
US8728479B2 (en) 2009-03-31 2014-05-20 The Trustees Of The University Of Pennsylvania Antigen-binding proteins comprising recombinant protein scaffolds
EP2421892A1 (en) 2009-04-20 2012-02-29 Pfizer Inc. Control of protein glycosylation and compositions and methods relating thereto
EP2446257B1 (en) 2009-06-26 2020-06-03 GE Healthcare Bio-Sciences AB A method in a chromatography system
US8586713B2 (en) 2009-06-26 2013-11-19 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
EP2470561A1 (en) 2009-08-27 2012-07-04 Novo Nordisk A/S Targeting tissue factor to activated platelets
SI2483310T1 (sl) 2009-09-29 2014-12-31 Roche Glycart Ag Bispecifiäśna agonistiäśna protitelesa receptorja smrti
PT2513134T (pt) 2009-12-18 2017-12-14 Novartis Ag Solução de lavagem e método para cromatografia de afinidade
SG182553A1 (en) 2010-01-22 2012-08-30 Boehringer Ingelheim Int Chromatographic method for purifying fc-containing proteins
CA2791918C (en) 2010-03-05 2019-11-19 Boehringer Ingelheim International Gmbh Selective enrichment of antibodies
WO2011118699A1 (ja) * 2010-03-24 2011-09-29 株式会社カネカ 免疫グロブリンに特異的に結合するタンパク質および免疫グロブリン結合性アフィニティーリガンド
FR2958936A1 (fr) 2010-04-14 2011-10-21 Sanofi Aventis Proteine de fusion robo1-fc et son utilisation dans le traitement des tumeurs
EP2558497A2 (en) 2010-04-15 2013-02-20 Amgen Inc. Human fgf receptor and beta-klotho binding proteins
JP6048972B2 (ja) 2010-04-23 2016-12-21 ジェネンテック， インコーポレイテッド ヘテロ多量体タンパク質の産生
KR101152036B1 (ko) 2010-04-27 2012-06-08 (주)셀트리온 컬럼 순환 및 시료 연속주입법을 이용한 단백질 ａ 크로마토그래피 정제 방법
US20130231464A1 (en) 2010-04-28 2013-09-05 Oncolmmune, Inc. Methods of use of soluble cd24 for therapy of rheumatoid arthritis
AU2011249782B2 (en) 2010-05-06 2014-10-02 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (LRP6) multivalent antibodies
EA022932B1 (ru) 2010-06-09 2016-03-31 Зимодженетикс, Инк. Димерные слитые белки vstm3 и связанные с ними композиции и способы
ES2671347T3 (es) 2010-06-21 2018-06-06 Kyowa Hakko Kirin Co., Ltd. Procedimiento para purificar una proteína que utiliza un aminoácido
US8883134B2 (en) 2010-10-20 2014-11-11 Handok Pharmaceuticals, Inc. Human interleukin-1 receptor antagonist—hybrid Fc fusion protein
UY33707A (es) 2010-11-04 2012-05-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
CA2813411C (en) 2010-11-05 2016-08-02 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
JP6092782B2 (ja) 2010-11-16 2017-03-08 エクセリミューン， インコーポレイテッド 組換えタンパク質の製造方法
JP2014502272A (ja) 2010-11-29 2014-01-30 ジーイー・ヘルスケア・バイオサイエンス・アクチボラグ アフィニティークロマトグラフィーマトリックス
EP2654915B1 (en) 2010-12-20 2018-10-24 GE Healthcare BioProcess R&D AB Affinity chromatography matrix
US9187555B2 (en) 2010-12-20 2015-11-17 Ge Healthcare Bio-Sciences Ab Affinity chromatography matrix
WO2012083425A1 (en) 2010-12-21 2012-06-28 The University Of Western Ontario Novel alkali-resistant variants of protein a and their use in affinity chromatography
JP5298242B2 (ja) 2010-12-21 2013-09-25 Ｊｓｒ株式会社 アフィニティークロマトグラフィー用担体およびイムノグロブリンを単離する方法
EP2658979B1 (en) 2010-12-27 2018-02-14 Alexion Pharmaceuticals, Inc. Compositions comprising natriuretic peptides and methods of use thereof
WO2012125735A1 (en) 2011-03-15 2012-09-20 Abott Laboratories An integrated approach to the isolation and purification of antibodies
EP2690173B1 (en) 2011-03-25 2019-07-03 Kaneka Corporation Protein for affinity-separation matrix
CA2830990A1 (en) 2011-03-25 2012-10-04 Kaneka Corporation Novel immunoglobulin-binding polypeptide
BR112013024933A2 (pt) 2011-03-29 2016-09-06 Glaxosmithkline Llc sistema tampão para purificação de proteínas
CN102757930A (zh) * 2011-04-27 2012-10-31 长春安贝生物科技有限公司 超低IgG新生牛血清生产工艺
US9663552B2 (en) 2011-06-01 2017-05-30 Novartis Ag Purification method for proteins, in particular antibodies, utilizing a wash solution comprising arginine at high pH for the affinity chromatography step
EP2728000B1 (en) 2011-06-03 2018-12-05 National Institute of Advanced Industrial Science And Technology Protein a mutant protein having reduced affinity in acidic region, and antibody capture agent
US9499608B2 (en) 2011-06-08 2016-11-22 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University Bispecific monoclonal antibody therapeutics against West Nile virus with improved CNS penetration
SG186552A1 (en) 2011-06-08 2013-01-30 Emd Millipore Corp Chromatography matrices including novel staphylococcus aureus protein a based ligands
CN103649125A (zh) 2011-06-22 2014-03-19 霍夫曼-拉罗奇有限公司 利用包含mhc i类的复合物通过循环中的病毒特异性细胞毒性t细胞清除靶细胞
CA2840552A1 (en) 2011-07-01 2013-01-10 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
JP6280499B2 (ja) 2011-07-08 2018-02-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｆｃ融合タンパク質の精製方法
CA2840944A1 (en) 2011-07-08 2013-01-17 Bayer Intellectual Property Gmbh Fusion proteins releasing relaxin and uses thereof
US20140228548A1 (en) 2011-09-01 2014-08-14 Human Genome Sciences Viral clearance methods
MX2014002996A (es) 2011-09-23 2014-05-28 Roche Glycart Ag Anticuerpos anti - egfr/anti - igf-1r bisespecificos.
US9958455B2 (en) 2011-09-29 2018-05-01 Seattle Genetics, Inc. Intact mass determination of protein conjugated agent compounds
EP2578286A1 (en) 2011-10-04 2013-04-10 Merck Patent GmbH Method and apparatus for chromatographic purification
US10344050B2 (en) 2011-10-27 2019-07-09 Genmab A/S Production of heterodimeric proteins
WO2013075740A1 (en) 2011-11-23 2013-05-30 Sanofi Antibody purification method
WO2013081540A1 (en) 2011-11-30 2013-06-06 Ge Healthcare Bio-Sciences Ab Affinity chromatography matrix
CA2858389A1 (en) 2011-12-15 2013-06-20 The Royal Institution For The Advancement Of Learning/Mcgill University Soluble igf receptor fc fusion proteins and uses thereof
EP2797959A4 (en) 2011-12-29 2015-08-26 Atyr Pharma Inc ASPARTYL-tRNA synthetase FC CONJUGATES
WO2013147691A1 (en) 2012-03-28 2013-10-03 Ge Healthcare Bio-Sciences Ab Affinity chromatography matrix
CA2868404A1 (en) 2012-04-05 2013-10-10 F. Hoffmann-La Roche Ag Bispecific antibodies against human tweak and human il17 and uses thereof
EP2656892A1 (en) 2012-04-23 2013-10-30 Merck Patent GmbH Chromatography method
US20140154270A1 (en) 2012-05-21 2014-06-05 Chen Wang Purification of non-human antibodies using kosmotropic salt enhanced protein a affinity chromatography
EP2854845B1 (en) 2012-06-01 2018-03-28 IBC Pharmaceuticals, Inc. Multimeric complexes with improved in vivo stability, pharmacokinetics and efficacy
EP2682168A1 (en) 2012-07-02 2014-01-08 Millipore Corporation Purification of biological molecules
SI3495387T1 (sl) 2012-07-13 2021-12-31 Roche Glycart Ag Bispecifična protitelesa proti VEGF/proti ANG-2 in njihova uporaba pri zdravljenju bolezni očesnih žil
CA2879814A1 (en) 2012-08-02 2014-02-06 Jn Biosciences Llc Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece
CA2876096A1 (en) 2012-08-02 2014-02-06 Petra Rueger Method for producing soluble fcr as fc-fusion with inert immunoglobulin fc-region and uses thereof
WO2014020069A1 (en) 2012-08-02 2014-02-06 F. Hoffmann-La Roche Ag Method for producing monomeric and multimeric molecules and uses thereof
CN109513003A (zh) 2012-08-14 2019-03-26 Ibc药品公司 用于治疗疾病的t-细胞重定向双特异性抗体
TWI633117B (zh) 2012-09-13 2018-08-21 必治妥美雅史谷比公司 結合至肌肉生長抑制素（ｍｙｏｓｔａｔｉｎ）以纖維連接蛋白爲主之支架結構域蛋白質
JP6276694B2 (ja) 2012-09-21 2018-02-07 株式会社カネカ アフィニティー分離マトリックス用タンパク質リガンド
US9107960B2 (en) 2012-12-13 2015-08-18 Immunimedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
WO2014124326A1 (en) 2013-02-08 2014-08-14 Stem Centrx, Inc. Novel multispecific constructs
EP2772289B1 (en) 2013-03-01 2015-05-06 ChromaCon AG Chromatographic process for enrichment and isolation
CA2903496C (en) 2013-03-14 2020-01-14 Emd Millipore Corporation Methods of increasing protein purity using protein a based chromatography
AU2013203043B2 (en) 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
CN114717206A (zh) 2013-03-15 2022-07-08 Atyr 医药公司 组氨酰-trna合成酶-fc缀合物
PE20151673A1 (es) 2013-03-15 2015-11-27 Genentech Inc POLIPEPTIDOS DE IL-22 Y PROTEINAS DE FUSION DE IL-22 Fc Y METODOS DE USO
CN104059133B (zh) 2013-03-18 2019-03-15 南京金斯瑞生物科技有限公司 一类突变的具有高耐碱特性的蛋白a及其应用
JP2016520586A (ja) 2013-05-08 2016-07-14 ザイムワークス，インコーポレイテッド 二重特異性ｈｅｒ２およびｈｅｒ３抗原結合性構築物
JP2016519145A (ja) 2013-05-15 2016-06-30 メディミューン リミテッド 組換え産生ポリペプチドの精製
WO2014192877A1 (ja) 2013-05-29 2014-12-04 Jsr株式会社 洗浄用組成物、タンパク質精製方法、及びタンパク質
JP2016531088A (ja) 2013-06-17 2016-10-06 アサナ・バイオサイエンシズ，リミテッド・ライアビリティ・カンパニー ５ｔ４標的化免疫融合分子および方法
RU2648154C2 (ru) 2013-07-09 2018-03-22 Аблбио Новые белки, специфично связывающиеся с двумя мишенями -dll4 и vegf-, и их применение
CN105377880B (zh) 2013-07-10 2020-08-07 通用电气医疗集团生物工艺研发股份公司 突变的免疫球蛋白结合多肽
AP2016009019A0 (en) 2013-07-25 2016-02-29 Novartis Ag Bioconjugates of synthetic apelin polypeptides
KR101809072B1 (ko) 2013-08-02 2017-12-14 화이자 인코포레이티드 항-cxcr4 항체 및 항체-약물 접합체
US20150093800A1 (en) 2013-09-05 2015-04-02 Genentech, Inc. Method for chromatography reuse
EP3903599A1 (en) 2013-09-25 2021-11-03 Bioverativ Therapeutics Inc. On-column viral inactivation methods
SG10201806917PA (en) 2013-10-15 2018-09-27 Seattle Genetics Inc Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
WO2015077891A1 (en) 2013-11-27 2015-06-04 Zymeworks Inc. Bispecific antigen-binding constructs targeting her2
KR102178323B1 (ko) 2013-11-29 2020-11-13 삼성전자주식회사 항 c-Met/항 Ang2 이중 특이 항체
BR112016012538A2 (pt) 2013-12-17 2017-09-26 Novartis Ag peptídeos citotóxicos e conjugados dos mesmos
SI3099692T1 (sl) 2014-01-27 2019-06-28 Pfizer Inc. Bifunkcionalna citotoksična zdravila
WO2015130766A1 (en) 2014-02-25 2015-09-03 Memorial Sloan-Kettering Cancer Center Antigen-binding proteins specific for hla-a2-restricted wilms tumor 1 peptide
JP6345800B2 (ja) 2014-03-17 2018-06-20 田辺三菱製薬株式会社 抗体−フィノマー複合体
JP2017517272A (ja) 2014-03-28 2017-06-29 ニューヨーク・ユニバーシティ Ｆｇｆ２３融合タンパク質
KR102430829B1 (ko) 2014-04-25 2022-08-09 리나트 뉴로사이언스 코프. 약물이 고도로 로딩된 항체-약물 접합체
EP3137186B1 (en) 2014-04-30 2021-01-27 Novo Nordisk A/S Methods for the purification of proteins using caprylic acid
EP3143049B1 (en) 2014-05-14 2019-08-21 F. Hoffmann-La Roche AG Her3/her2 bispecific antibodies binding to the beta-hairpin of her3 and domain ii of her2
CA2946503C (en) 2014-05-28 2022-11-22 Zymeworks Inc. Modified antigen binding polypeptide constructs and uses thereof
EP3154997B9 (en) 2014-06-13 2021-04-14 Novartis AG Auristatin derivatives and conjugates thereof
CA2951766A1 (en) 2014-06-13 2015-12-17 Lupin Limited Process for the purification of tnfr:fc fusion protein
US9777073B2 (en) 2014-07-21 2017-10-03 Wuhan Yzy Biopharma Co., Ltd. Construction and application of bispecific antibody EpCAM×CD3
AR101262A1 (es) 2014-07-26 2016-12-07 Regeneron Pharma Plataforma de purificación para anticuerpos biespecíficos
KR102259232B1 (ko) 2014-08-25 2021-05-31 삼성전자주식회사 항 c-Met/항 Ang2 이중 특이 항체
HUE049325T2 (hu) 2014-08-28 2020-09-28 Pfizer Stabilitás modulátor linker antitest-hatóanyag konjugátumokhoz történõ alkalmazásra
US11279771B2 (en) 2014-09-17 2022-03-22 Novo Nordisk A/S Antibodies capable of binding two epitopes on tissue factor pathway inhibitor (1-161)
MX2016012572A (es) * 2014-10-24 2016-12-14 Gemtier Medical (Shanghai) Inc Aguja desechable para puncion segura en transfusion venosa.
US11566082B2 (en) * 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
US20160158377A1 (en) 2014-12-09 2016-06-09 Abbvie Inc. BCL-XL Inhibitory Compounds and Antibody Drug Conjugates Including the Same
AU2015360609A1 (en) 2014-12-09 2017-06-29 Abbvie Inc. Antibody drug conjugates with cell permeable Bcl-xL inhibitors
DK3233907T3 (da) 2014-12-19 2021-06-07 Genmab As Bispecifikke heterodimeriske proteiner hos gnavere
CA2975410A1 (en) 2015-04-07 2016-10-13 Immunomedics, Inc. Y-90-labeled anti-cd22 antibody (epratuzumab tetraxetan) in refractory/relapsed adult cd22+ b-cell acute lymphoblastic leukemia
US11820807B2 (en) 2015-06-12 2023-11-21 Ubi Pharma Inc Immunoglobulin fusion proteins and uses thereof
US20180194861A1 (en) 2015-07-10 2018-07-12 Abbvie Inc. IgM- or IgE-Modified Binding Proteins and Uses Thereof
GB201515339D0 (en) 2015-08-28 2015-10-14 Ge Healthcare Bio Sciences Ab A seperation matrix and a method of seperating antibodies
KR102692686B1 (ko) 2015-09-25 2024-08-06 에프. 호프만-라 로슈 아게 소르타아제 접합 루프를 포함하는 재조합 면역글로불린 중쇄 및 이의 접합체
JP2018536389A (ja) 2015-10-02 2018-12-13 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト メソテリンとｃｄ３に結合する二重特異性細胞活性化抗原結合分子
MY198560A (en) 2015-10-02 2023-09-05 Hoffmann La Roche Bispecific antibodies specific for a costimulatory tnf receptor
JP7074665B2 (ja) 2015-10-07 2022-05-24 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 共刺激ｔｎｆ受容体に対する四価の二重特異性抗体発明の分野
TWI812873B (zh) 2015-11-30 2023-08-21 美商輝瑞股份有限公司 用於部位專一性接合之抗體和抗體片段
WO2017194597A1 (en) 2016-05-11 2017-11-16 Ge Healthcare Bioprocess R&D Ab Separation matrix
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method

Also Published As

Publication number Publication date
US20210147577A1 (en) 2021-05-20
AU2015348641B2 (en) 2020-06-25
RU2017115345A (ru) 2018-12-19
RU2017115345A3 (pt) 2019-04-02
JP2020184999A (ja) 2020-11-19
JP6770727B2 (ja) 2020-10-21
CN107001432A (zh) 2017-08-01
JP6724000B2 (ja) 2020-07-15
EP3221338B1 (en) 2020-10-28
SI3221347T1 (sl) 2020-11-30
RU2017115342A3 (pt) 2019-04-05
EP3757124A1 (en) 2020-12-30
KR102697609B1 (ko) 2024-08-26
KR102552335B1 (ko) 2023-07-07
US11566082B2 (en) 2023-01-31
RU2017115342A (ru) 2018-12-19
US20180327512A1 (en) 2018-11-15
US20200079878A1 (en) 2020-03-12
EP3757123B1 (en) 2024-08-21
CN118546242A (zh) 2024-08-27
SG11201702796WA (en) 2017-05-30
DK3757123T3 (da) 2024-09-23
SG11201703053PA (en) 2017-05-30
KR20170085502A (ko) 2017-07-24
ES2817900T3 (es) 2021-04-08
DE112015005181T5 (de) 2017-08-24
CN107001448A (zh) 2017-08-01
US20170334954A1 (en) 2017-11-23
EP3221338A1 (en) 2017-09-27
AU2015348640A1 (en) 2017-04-27
JP2017533924A (ja) 2017-11-16
KR20170078693A (ko) 2017-07-07
EP3221347B1 (en) 2020-08-19
EP3757123A1 (en) 2020-12-30
US20230331870A1 (en) 2023-10-19
WO2016079034A1 (en) 2016-05-26
RU2712882C2 (ru) 2020-01-31
JP2022062096A (ja) 2022-04-19
JP7015868B2 (ja) 2022-02-03
RU2701695C2 (ru) 2019-09-30
US10501557B2 (en) 2019-12-10
AU2015348640B2 (en) 2021-07-15
DK3221347T3 (da) 2020-09-21
AU2015348641A1 (en) 2017-04-27
JP2020178696A (ja) 2020-11-05
CN107001432B (zh) 2022-02-18
EP3221347A1 (en) 2017-09-27
JP2017536819A (ja) 2017-12-14
WO2016079033A1 (en) 2016-05-26

Similar Documents

Publication Publication Date Title
BR112017008106A2 (pt) polipeptídeo de ligação a fc, multímero, ácido nucleico ou vetor, sistema de expressão, matriz de separação, e, método para isolar uma imunoglobina.
CL2018000124A1 (es) Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer epitelial de ovario y otros tipos de cáncer
CY1124921T1 (el) Μεθοδοι για την εκχυλιση και τον καθαρισμο μη μετουσιωμενων πρωτεϊνων
EA201891614A1 (ru) Химерные белки и способы иммунотерапии
BR112017026523A2 (pt) vetor recombinante, adenovírus recombinante, composição, uso de um vetor recombinante, de um adenovírus recombinante ou de uma composição, método para induzir uma resposta imune em um indivíduo, e, polinucleotídeo isolado.
EA201892250A1 (ru) Вакцина против rsv
BR112017007202A2 (pt) receptores de célula t
UA120917C2 (uk) Химерний білок фактора viii та його застосування
NZ629843A (en) Identification of channelrhodopsin-2 (chop2) mutations and methods of use
BR112018067536A2 (pt) sistema de transpóson e métodos de uso
WO2018081592A3 (en) Compositions and methods for the production of compounds
ES2721309T3 (es) Composición para preparar tagatosa y método para preparar tagatosa a partir de fructosa
PH12015502849A1 (en) Biomarkers for cognitive dysfunction diseases and method for detecting cognitive dysfunction disease using biomarkers
BR112017009790A2 (pt) anticorpos direcionados ao anti-ang2 e métodos de uso
WO2016130628A8 (en) Griffithsin mutants
BR112019004459A2 (pt) métodos para purificar anticorpos
EA201891878A1 (ru) Очистка белков
BR112016026842A2 (pt) preparação compreendendo fator viii e peptídeos de fator de von willebrand
BR112017020308A2 (pt) udp-glicosiltransferases
BR112018001202A2 (pt) anticorpo monoclonal, ácido nucleico, vetor, célula hospedeira, composição farmacêutica e método
CL2017000200A1 (es) Célula huésped mejorada para producir proteinas
BR112016016737A2 (pt) Peptídeos, dispositivos e métodos para detecção de anticorpos contra anaplasma
WO2015107363A3 (en) Mycobacterial antigen composition
MX2017007105A (es) Variantes de lipasa y polinucleotidos que las codifican.
BR112017018703A2 (pt) peptídeo derivado de gpc3, composição farmacêutica para tratamento ou prevenção de câncer usando o mesmo, indutor de imunidade, e método para produzir células de apresentação de antígeno

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25D Requested change of name of applicant approved

Owner name: CYTIVA BIOPROCESS RANDD AB (SE)

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09X Republication of the decision to grant [chapter 9.1.3 patent gazette]